Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 102

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 102
---
225 70,610 3,615 5%General and administrative27,278 25,742 1,536 6%93,417 83,697 9,720 12%Impairment of assets— 185 (185)(100)%20,505 614 19,891 3240%Intangible asset amortization - operating expenses622 880 (258)(29)%1,865 2,499 (634)(25)%Total operating expenses68,336 66,993 1,343 2%239,977 207,424 32,553 16%Income from operations22,946 12,017 10,929 91%20,582 11,967 8,615 72%Other income (loss), net(4,057)4,831 (8,888)(184)%6,985 10,334 (3,349)(32)%Income before income taxes18,889 16,848 2,041 12%27,567 22,301 5,266 24%Income tax (benefit) provision(248)1,693 (1,941)(115)%2,363 3,276 (913)(28)%Net income$19,137 $15,155 $3,982 26%$25,204 $19,025 $6,179 32%Other Operating Data:    Diagnostic tests reported43,679 36,792 6,887 19%124,198 103,818 20,380 20%Product tests sold2,209 2,240 (31)(1)%7,311 7,661 (350)(5)%Total test volume45,888 39,032 6,856 18%131,509 111,479 20,030 18%Depreciation and amortization expense$5,267 $5,878 $(611)(10)%$16,117 $17,206 $(1,089)(6)%Stock-based compensation expense$10,757 $8,747 $2,010 23%$32,700 $26,620 $6,080 23%

Revenue

Revenue increased $16.0 million for the three months ended September 30, 2025 compared to the same period in 2024. This was primarily due to